Alembic Pharmaceuticals has received USFDA approval for Pregabalin Capsules, indicated for management of neuropathic pain associated with certain illnesses. The drug is a therapeutically equivalent to the reference listed drug Lyrica Capsules of PF Prism CV.
The company will produce Pregabalin Capsules in the strengths of 25 mg, 50 mg, 75 mg, 100 mg, 150 mg, 200 mg, 225 mg, and 300 mg.
According to market estimates, Pregabalin Capsules have an estimated market size of $5.47 billion for 12 months ending December 2018.
Pregabalin Capsule is indicated for management of neuropathic pain associated with diabetic peripheral neuropathy, management of postherpetic neuralgia, adjunctive therapy for the treatment of partial-onset seizures in patients 17 years of age and older, management of fibromyalgia and management of neuropathic pain associated with spinal cord injury.
Company Profile : Alembic Pharmaceuticals Ltd